Pilot Study of Feasibility and Safety of Personalized Autologous Cluster of Differentiation 8 (CD8+) T Cell Therapy Plus Anti-PD1Antibody in Advanced Solid Malignancies
Not yet recruiting
Phase of Trial: Phase I
Latest Information Update: 24 Apr 2017
At a glance
- Drugs Pembrolizumab (Primary) ; T cell replacement therapy (Primary) ; Cyclophosphamide; Interleukin-2
- Indications Gastrointestinal cancer
- Focus Adverse reactions
- 19 Apr 2017 Planned primary completion date changed from 1 Feb 2021 to 1 Aug 2021.
- 19 Apr 2017 Planned initiation date changed from 1 Feb 2017 to 1 Aug 2017.
- 14 Nov 2016 Planned primary completion date changed from 1 Oct 2020 to 1 Feb 2021.